A Phase II Study of the Aurora A Kinase Inhibitor Alisertib in Combination With 7+3 Induction Chemotherapy in Patients With High-risk Acute Myeloid Leukemia
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 21 Aug 2017
At a glance
- Drugs Alisertib (Primary) ; Cytarabine (Primary) ; Daunorubicin (Primary) ; Idarubicin (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 15 Aug 2017 Planned End Date changed from 1 Sep 2024 to 1 Aug 2018.
- 15 Aug 2017 Planned primary completion date changed from 1 Jan 2020 to 1 Sep 2017.
- 15 Aug 2017 Status changed from recruiting to active, no longer recruiting.